Top member reports
Company Report
Last edited 3 years ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#38
Performance (79m)
4.4% pa
Followed by
170
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#ASX Announcements
stale
Added 3 years ago

Great news that so many of those in need may now have a second chance of a full/fuller life: I have also added in RL this morning.

Remplir™ nerve repair device receives Australian regulatory approval:

Orthocell receives Australian regulatory (TGA) approval for Remplir™ for use in peripheral nerve repair procedures

Remplir™ nerve repair device represents a paradigm shift in product design and application to facilitate the regeneration of damaged peripheral nerves

Significant Australian addressable market, with 11,7801 surgical repairs of peripheral nerves completed in public and private hospitals in the 2019/20 financial year

Australian reimbursement application planned for Q2 CY2022 which defines the minimum benefit value private insurers pay for Remplir™

Approval validates the CelGro® platform technology and positions Orthocell well to achieve further international regulatory approvals in nerve repair